[Federal Register Volume 78, Number 142 (Wednesday, July 24, 2013)]
[Notices]
[Page 44575]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-17720]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration


Sickle Cell Disease Treatment Demonstration Program

AGENCY: Health Resources and Services Administration (HRSA), Department 
of Health and Human Services (HHS).

ACTION: Request for Class Deviation for Non-Competitive Extension: 
Sickle Cell Disease Treatment Demonstration Program (U1E) Awards to 
Three Currently Funded Grantees.

-----------------------------------------------------------------------

SUMMARY: HRSA currently has nine programs that are funded through 
competitive grant awards under the Sickle Cell Disease Treatment 
Demonstration Program. Three of these awards will end on August 31, 
2013, prior to the end of the other six awards. HRSA intends to 
implement a non-competitive extension of the project period for the 
three grants that will end in 2013. This will allow improved data 
gathering from each of the grantees in the program, which will be used 
in a report for Congress that is mandated by the legislation 
authorizing the grant. In addition, the program will benefit from cost 
savings realized from having the program completed in a consolidated 
funding cycle.

SUPPLEMENTARY INFORMATION:
    Intended Recipients of the Award: The three incumbent grantees of 
record (listed below).
    Amount of the Non-Competitive Awards: Up to $390,000 per grantee.
    CFDA Number: 93.365.
    Period of Supplemental Funding: 9/1/2013-8/30/2014.

    Authority: Section 712(c) of the American Jobs Creation Act of 
2004, Pub. L. 108-357.

    Justification: The Sickle Cell Disease Treatment Demonstration 
Program provides grants to evaluate the use of strategies in improving 
sickle cell care. The extension will allow the Maternal and Child 
Health Bureau to fully assess the impact of the program by allowing 
data to be gathered on the health outcomes and impact of the Sickle 
Cell Disease Treatment Demonstration Program from all grantees on the 
same timeline and in a standard format. Currently, three grantees are 
scheduled to end prior to the end of the other grantees, leaving a 
period in which data would not be gathered from these sites. Data 
gathered from each of the grantees in the program will be used in a 
report for Congress that is mandated by the legislation authorizing the 
grant. In addition, the program will benefit from cost savings realized 
from having the program completed in a consolidated funding cycle.

FOR FURTHER INFORMATION CONTACT: Edward Donnell Ivy, M.D., M.P.H, 
Genetic Services Branch, Division of Services for Children with Special 
Health Needs, Maternal and Child Health Bureau, Health Resources and 
Services Administration, 5600 Fishers Lane, Room 18A-19, Rockville, MD 
20857; 301.443.9775; [email protected].

                                       Maternal and Child Health Bureau Selected Programs Extensions With Funding
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                              Revised
      Grantee/organization name           Grant No.          State         Project start    Project end     project end       FY 2012         FY 2013
                                                                               date            date            date        Appropriation   Appropriation
--------------------------------------------------------------------------------------------------------------------------------------------------------
Children's Hospital & Research Center      U1EMC16492  CA                       9/1/2009       8/31/2013       8/30/2014        $390,000        $390,000
University of Colorado at Denver.....      U1EMC16490  CO                       9/1/2009       8/31/2013       8/30/2014         390,000         390,000
Newark Beth Israel Medical Center....      U1EMC16491  NJ                       9/1/2009       8/31/2013       8/30/2014         390,000         390,000
--------------------------------------------------------------------------------------------------------------------------------------------------------


    Dated: July 17, 2013.
Mary K. Wakefield,
Administrator.
[FR Doc. 2013-17720 Filed 7-23-13; 8:45 am]
BILLING CODE 4165-15-P